Rademacher raises #8.6 million for drug development

Investee Company – Rademacher Group Limited

Investee Company Country – UK

Investee Company Business Type – Pharmaceuticals

Type of Financing – Second round

Equity Providers – Johnson & Johnson Development Corporation, Northern Ventures, Apax Partners, and Advent Venture Partners.

Equity Leader (Individuals)- Susan Lambert, Johnson & Johnson Development Corporation

Debt Providers – N/A

Debt Type – N/A

Debt Leader (Individual) – N/A

Equity Amount – £8.6 million

Total Deal Value – £8.6 million

Other Advisors -Speechley, Bircham and Company

Comments – Rademacher, based in Oxford, has previously received financing from both Apax Partners and Advent Venture Partners. These existing investors were joined in this round by Northern Ventures and Johnson & Johnson Development Corporation (JJDC), who invested £3.5 million.

The funding will be used to further Rademacher’s Research and Development programmes into disorders such as diabetes.

Rademacher’s Chairman said: “We are delighted that JJDC has chosen to invest in Rademacher. With Northern Ventures, Apax and Advent Venture Partners also participating in this round, we have attracted an excellent investor base.”

The company is also discussing the establishment of licences for other developmental products with major healthcare companies.

Rademacher’s scientific programmes are based on the analysis and sythesis of signalling molecules (phosphoglycan messengers or PGMs), which mediate the signalling actions of the hormones that control cell activity. This approach has the potential to develop new treatments for disorders such as obesity, diabetes, asthma, cancer, and degenerative neurological disorders, currently controlled by recombinant gene products.